A summary of second-line randomized studies of aromatase inhibitors (Q34535220)

2 August 2017

1 reference

title

A summary of second-line randomized studies of aromatase inhibitors (English)

1 reference

2 August 2017

A U Buzdar

1

1 reference

2 August 2017

publication date

1 December 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

2 August 2017

published in

1 reference

2 August 2017

volume

79

1 reference

2 August 2017

issue

1-5

1 reference

2 August 2017

page(s)

109-114

1 reference

Tamoxifen in advanced breast cancer

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Tamoxifen for breast cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Letrozole: updated duration of response

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Exemestane: a review of its use in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Risks and benefits of aromatase inhibitors in postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

Exemestane (FCE 24304), a new steroidal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900150-9

7 January 2021

10.1016/S0960-0760(01)00150-9

Identifiers

DOI

1 reference

2 August 2017

1 reference